NCT06476119招募中不适用
OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 490
- 试验地点
- 28
- 主要终点
- Disease recurrence Free Interval (DRFI) - optimalisation cohort per-protocol population
研究概览
简要总结
The aim of this study is to investigate whether subjects with breast cancer that have certain favorable features, after performing the surgery and radiation, the chemotherapy can be safely omitted in the treatment. In addition, the investigation looks at whether the omission of chemotherapy ensures a better quality of life. Participants decide, in consultation with their treating physician, whether they choose to be treated with adjuvant chemotherapy or not.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female or male patients;
- •>=18 years;
- •Written informed consent;
- •TNBC (defined as: invasive carcinoma; ER/PR expression 0-9%; Human Epidermal Growth Factor Receptor 2 [HER2] negative [0, 1+ or 2+ on immunohistochemistry, without HER2 amplification on in-situ hybridization]) on the diagnostic biopsy and the surgical specimen;
- •Pathological stage I TNBC (according to the TNM staging 8th edition):
- •pT1a/b/c (≤2 cm), confirmed by an invasive component of ≤2 cm on the surgical specimen (microinvasive disease [pT1mi, ≤1 mm) is not allowed);
- •pN0, confirmed by absence of malignant cells in the sentinel lymph node or any other lymph node after surgery (isolated tumor cells [N0(i+)] are not allowed);
- •No evidence of nodal or distant metastases (cN0M0) on pre and/or postoperative imaging examinations (performed following local/national guidelines, but must include an 18F-fluorodeoxyglucose positron emission tomography/computed tomography [18F-FDG-PET/CT, at least from skull base to upper legs] or computed tomography [CT] of neck/chest/abdomen/pelvis [CT only if 18F-FDG-PET/CT would not be available; 18F-FDG-PET/CT mandatory in the Netherlands]);
- •sTIL score of ≥50% for patients ≥40 years at the time of TNBC diagnosis and ≥75% for patients <40 years at the time of TNBC diagnosis on an H&E FFPE tissue slide on the surgical specimen, according to International Immuno-Oncology Biomarker Working Group on Breast Cancer (formerly International TILs Working Group) guidelines, by local and central review
- •Has undergone curative breast surgery (breast-conserving surgery or mastectomy and surgical axillary staging [including at least sentinel lymph node procedure]);
- •Absence of recurrence between curative breast surgery and expression of patient preference;
- •Eligible for radiotherapy (if indicated).
排除标准
- •Prior disease history of invasive and/or non-invasive breast cancer, or ongoing treatment for invasive and/or non-invasive breast cancer;
- •Multifocal, multicentric or bilateral breast cancer at the time of screening;
- •Administration of neoadjuvant systemic therapy;
- •Presence of lymphovascular invasion on the diagnostic biopsy and/or the surgical specimen;
- •Other invasive malignancy within 5 years prior to inclusion, with the exception of ade-quately treated non-melanoma skin cancer, localized cervical cancer, localized and Gleason ≤6 prostate cancer;
- •Uncontrolled severe illness or medical condition;
- •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the in the trial.
研究组 & 干预措施
Optimisation cohort
patients will be treated with surgery and adjuvant radiotherapy following local/national guidelines, while chemotherapy will be omitted
干预措施: No adjuvant chemotherapy (Other)
Control cohort
patients will be treated with surgery, adjuvant radiotherapy and adjuvant chemotherapy following local/national guidelines
干预措施: Adjuvant chemotherapy (Drug)
结局指标
主要结局
Disease recurrence Free Interval (DRFI) - optimalisation cohort per-protocol population
时间窗: up to 96 months after inclusion of the last patient
Number of patients with distant recurrence or death in per-protocol population of the optimisation cohort
次要结局
- Fear of recurrence(up to 2 years after inclusion)
- Worries about health(up to 2 years after inclusion)
- disease recurrence free survival (DRFS) - optimalisation cohort the intention-to-treat population(up to 96 months after inclusion of the last patient)
- Recurrence-free survival (RFS) - control cohort(up to 96 months after inclusion of the last patient)
- Overal Survival (OS) - optimalisation cohort per-protocol population(up to 96 months after inclusion of the last patient)
- Overal Survival (OS) - optimalisation cohort intention-to-treat population(up to 96 months after inclusion of the last patient)
- Overal Survival (OS) - control cohort(up to 96 months after inclusion of the last patient)
- Health related Quality of Life (HRQoL) - (European Organisation on Research and Treatment of Cancer) EORTC questionnaire QLQ-C30(up to 2 years after inclusion)
- Cost effectiveness measured per incremental cost-effectiveness ratio (ICER)(up to 2 years after inclusion)
- Disease recurrence Free Interval (DRFI) - control cohort(up to 96 months after inclusion of the last patient)
- Invasive disease-free survival (IDFS) - optimalisation cohort per-protocol population(up to 96 months after inclusion of the last patient)
- Recurrence-free survival (RFS) - optimalisation cohort per-protocol population(up to 96 months after inclusion of the last patient)
- Cost effectiveness measured by quality-adjusted-life years (QALYs)(up to 2 years after inclusion)
- Invasive disease-free survival (IDFS) - control cohort(up to 96 months after inclusion of the last patient)
- Recurrence-free survival (RFS) - optimalisation cohort the intention-to-treat population(up to 96 months after inclusion of the last patient)
- Disease recurrence Free Interval (DRFI) - optimalisation cohort intention to treat population(up to 96 months after inclusion of the last patient)
- Invasive disease-free survival (IDFS) - optimalisation cohort intention-to-treat population(up to 96 months after inclusion of the last patient)
- disease recurrence free survival (DRFS) - optimalisation cohort per-protocol population(up to 96 months after inclusion of the last patient)
- disease recurrence free survival (DRFS) - control cohort(up to 96 months after inclusion of the last patient)
- Health related Quality of Life (HRQoL) - (European Organisation on Research and Treatment of Cancer) EORTC questionnaire QLQ-BR45(up to 2 years after inclusion)
研究者
研究点 (28)
Loading locations...
相似试验
Unknown
4 期
Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency ElectrocoagulationBreast CancerNCT01216254Medical University of Gdansk150
进行中（未招募）
不适用
A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer PatientsBreast CancerNCT03983382Memorial Sloan Kettering Cancer Center190
已完成
不适用
The Involvement of Breast Cancer Patients During Oncological ConsultationsBreast CancerNCT01510964Azienda Ospedaliera Universitaria Integrata Verona300
进行中（未招募）
不适用
Subclinical Lymphedema Treatment StudyBreast Cancer-related Subclinical LymphedemaNCT03292198Mercy Research267
已完成
不适用
Patient Centered Randomized Controlled TrialEarly-Stage Breast CancerNCT00233077Icahn School of Medicine at Mount Sinai374